(86 days)
The ultrasound diagnostic system and probes are designed to obtain ultrasound images and analyze body fluids. The clinical applications include: Fetal/Obstetrics, Abdominal, Gynecology, Pediatric, Small Organ, Neonatal Cephalic, Adult Cephalic, Trans-rectal, Trans-vaginal, Muscular-Skeletal (Conventional, Superficial), Urology, Cardiac Adult, Cardiac Pediatric and Peripheral vessel.
The HERA 110 is general purpose, mobile, software controlled, diagnostic ultrasound system. Its function is to acquire ultrasound data and to display the data as B-mode, M-mode, Pulsed wave (PW) Doppler, Continuous wave (CW) Doppler, Color Doppler Imaging (TDI), Tissue Doppler Wave (TDW), Power Amplitude Doppler. Pulse Inversion Harmonic Imaging (S-Harmonic), Directional Power Doppler (S-Flow), Color M-Mode, 3D Imaging Mode, 4D Imaging Mode, Elastoscan+ Mode, Tissue Harmonic Imaging, MV-Flow Mode or as a combination of these modes. The HERA I10 also gives the operator the ability to measure anatomical structures and offers analysis packages that provide information that is used to make a diagnosis by competent health care professionals. The HERA I10 has real time acoustic output display with two basic indices, a mechanical index and a thermal index, which are both automatically displayed.
The provided text is a 510(k) Summary for the Samsung Medison HERA I10 Diagnostic Ultrasound System. This type of FDA submission aims to demonstrate substantial equivalence to a legally marketed predicate device, rather than proving safety and efficacy through extensive clinical trials. Therefore, the document explicitly states:
"The subject of this premarket submission, HERA I10, did not require clinical studies to support substantial equivalence." (Page 24)
This means that the information you've requested regarding acceptance criteria and a study proving device performance in the context of AI/human reader studies, ground truth establishment, expert adjudication, and large-scale sample sizes for training and testing is not present in this document. The submission focuses on demonstrating that the HERA I10 has equivalent technological characteristics, intended uses, and safety standards as its predicate device (HERA W10, K182595).
The "studies" mentioned are non-clinical and primarily cover:
- Acoustic output
- Biocompatibility
- Cleaning and disinfection effectiveness
- Thermal, electrical, electromagnetic, and mechanical safety
- Software/firmware functionality (evaluated against the predicate's test criteria to ensure image quality was not compromised)
The acceptance criteria for this submission revolve around confirming compliance with relevant industry standards (e.g., IEC 60601-1, ISO 14971, ISO 10993-1, NEMA UD 2 & 3) and demonstrating that the device functions as intended without introducing new safety or effectiveness concerns compared to the predicate.
In summary, based solely on the provided text, the document does not contain the specific information requested in points 1-9 as it explicitly states that clinical studies were not required.
If you are looking for information on acceptance criteria and performance studies for an AI-powered medical device, you would typically need to consult a different type of FDA submission (e.g., De Novo, PMA, or an AI/ML-specific 510(k) where clinical performance data is required). This document is for a general diagnostic ultrasound system and its equivalence to a previous version.
§ 892.1550 Ultrasonic pulsed doppler imaging system.
(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.